Cette polypharmacologie unique genere un profil d'action combinant trois dimensions distinctes : pigmentation cutanee active via MC1R sur les melanocytes epidermiques, stimulation sexuelle centrale via MC3R/MC4R hypothalamique (erections spontanees chez l'homme, stimulation libidinale chez les deux sexes), et modulation de l'appetit via MC4R avec effet anorexigene transitoire
In 1978, Clark11 reported an increased incidence of cutaneous melanoma in families with multiple melanocytic lesions, introducing the melanoma tumor progression model from melanocytic nevi.11,12 At the time, Clark used the term B-K mole syndrome using the initials of the patients surnames.11 Currently, the terms AMS, Dysplastic Nevus Syndrome and Familial Atypical Multiple-Mole Melanoma Syndrome (FAMMM) have been employed.12 In 1985, Elder13 extended the theory of nevus-melanoma for sporadic dysplastic nevi as a possible precursor to sporadic melanoma
Liverpool Hospital dermatologist, Associate Professor Deshan Sebaratnam, said melanoma was a major worry, not to mention the fact the drug was illegal to advertise and supply in Australia
[Content Brief] [4]
Melanotan 2 | Benefits and Research Applications MT1 and MT2 have shown various potential benefits thanks to their action on the melanocortin receptors